These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28448657)

  • 1. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
    Drögemöller BI; Monzon JG; Bhavsar AP; Borrie AE; Brooks B; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Aminkeng F; Amstutz U; Hildebrand CA; Gunaretnam EP; Critchley C; Chen Z; Brunham LR; Hayden MR; Ross CJD; Gelmon KA; Carleton BC
    JAMA Oncol; 2017 Nov; 3(11):1558-1562. PubMed ID: 28448657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further Investigation of the Role of
    Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
    Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
    [No Abstract]   [Full Text] [Related]  

  • 3. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy.
    Sanchez VA; Dinh PC; Monahan PO; Althouse S; Rooker J; Sesso HD; Dolan ME; Weinzerl M; Feldman DR; Fung C; Einhorn LH; Frisina RD; Travis LB
    JAMA Oncol; 2024 Jul; 10(7):912-922. PubMed ID: 38842797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
    Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
    Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
    Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
    J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
    Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
    Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin-based therapy.
    Noszek L; Budai B; Prekopp P; Széchenyi R; Szőnyi M; Talpai S; Nagyiványi K; Bíró K; Géczi L
    Laryngoscope; 2017 Aug; 127(8):E277-E282. PubMed ID: 27666741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
    Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
    Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
    Zhang X; Trendowski MR; Wilkinson E; Shahbazi M; Dinh PC; Shuey MM; ; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Huddart R; Martin NE; Sanchez VA; Frisina RD; Einhorn LH; Cox NJ; Travis LB; Dolan ME
    Cancer Med; 2022 Jul; 11(14):2801-2816. PubMed ID: 35322580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variants in
    Wheeler HE; Gamazon ER; Frisina RD; Perez-Cervantes C; El Charif O; Mapes B; Fossa SD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kollmannsberger C; Kim J; Mushiroda T; Kubo M; Ardeshir-Rouhani-Fard S; Einhorn LH; Cox NJ; Dolan ME; Travis LB
    Clin Cancer Res; 2017 Jul; 23(13):3325-3333. PubMed ID: 28039263
    [No Abstract]   [Full Text] [Related]  

  • 13. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
    Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
    Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
    Xu H; Robinson GW; Huang J; Lim JY; Zhang H; Bass JK; Broniscer A; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Fisher M; Cohn R; Yamashita T; Teitz T; Zuo J; Onar-Thomas A; Gajjar A; Stewart CF; Yang JJ
    Nat Genet; 2015 Mar; 47(3):263-6. PubMed ID: 25665007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
    Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
    Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
    Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
    Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
    Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
    Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
    Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
    J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment.
    Moore B; Sheets G; Doss J; Umrigar A; Norman M; Fang Z; Prasad P; Musso A; Clay S; Tsien F
    Am J Audiol; 2023 Sep; 32(3):657-664. PubMed ID: 37532243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.
    Lanvers-Kaminsky C; Ciarimboli G
    Pharmacogenomics; 2017 Dec; 18(18):1683-1695. PubMed ID: 29173064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.